Abnormalities in the vascular endothelium such as impaired vasodilation can contribute to atherosclerosis and hypertension. Here we have performed a single-center randomized clinical trial to evaluate the efficacy of 4 months of a continuous Mediterranean diet (MD) regimen as compared to 4 cycles of fasting mimicking diet (FMD) administered for only 5 days/month on endothelial function, measured as reactive hyperemia index (RHI) and large/small-resistance artery compliance (AC1/AC2), and on other cardiometabolic risk factors, in hypertensive patients with obesity/excess weight [both sexes, body mass index ( BMI) ≥ 28, RHI ≤ 2.0, and/or small-resistance artery compliance (AC2) ≤ 5.0]. At the end of the intervention period, FMD but not MD decreased RHI ( p = 0.0023) compared to baseline with no increase in the portion of patients with abnormal RHI. Both FMD and MD improved PULS cardiac test score; evaluating the risk of cardiovascular events. FMD and MD did not show any significant change in either AC1 or AC2 compared to baseline. Both FMD and MD led to comparable decreases in weight, waist circumference, BMI, body fat mass and % body fat, total cholesterol, and leptin. FMD decreased HbA1c ( p = 0.0059) and IGF-1 ( p = 0.0427), while MD decreased glucose ( p = 0.0488), HOMA-IR ( p = 0.0476), and HDL-C ( p = 0.0419). None of the parameters were significantly different between the FMD vs. MD group at the end of the intervention period. During the 3-month follow-up period, the FMD and MD groups continued to display weight and BMI reduction; however, the MD group also lost fat free mass (FMD vs. MD, p = 0.0498). In summary, both MD and FMD reduced a range of cardiometabolic risk factors, but FMD also decreased RHI, a change associated with either impaired functional integrity of vascular endothelial cells but also with vascular rejuvenation, with the latter being more likely considering the improved cardiometabolic profile, reduced PULS cardiac score and calculated heart age, and unaltered arterial compliance in the FMD group. MD but not FMD cycles caused loss of lean body mass.
Conflicts severely disrupt care for patients with kidney failure, often limiting access to dialysis. In these challenging settings, conservative kidney management (CKM) emerges as a compassionate alternative focused on quality of life and symptom relief. This study explores how conflict conditions shape nephrologists' perceptions and implementation of CKM across the Middle East and North Africa (MENA) region. A web-based survey was distributed across 17 Arabic-speaking MENA countries over 3 months in 2022. Responses were divided into two groups according to the country's conflict status. Of the 334 nephrologist respondents, 66 were practicing in conflict zones and 268 in nonconflict zones. Conflict zone respondents were more likely to work part-time and less likely to be female. Dialysis in conflict zones was more likely funded by charitable sources (odds ratio [OR], 4.22; 95% confidence interval [CI], 1.36 to 13.07). Compared with nonconflict zones, nephrologists in conflict areas reported significantly less access to palliative care (OR, 3.36; 95% CI, 1.3 to 8.68) and cited lack of CKM training and limited access to CKM programs as barriers to its implementation (OR, 2.59; 95% CI, 1.24 to 5.38 and OR, 3.42; 95% CI, 1.59 to 7.35; respectively). While overall awareness of CKM was similar, those in conflict zones expressed greater moral and religious discomfort with withholding dialysis. These findings underscore important ethical, operational, and access-related disparities in CKM delivery in conflict zones in the MENA region. Addressing these gaps through supportive ethical policies focusing on procedural and distributive justice, increased nephrologists' awareness and training, and enhanced efforts to strengthen palliative care services are essential tools for establishing CKM as a viable and ethical approach for patients in conflict-affected regions.
Autosomal dominant polycystic kidney disease (ADPKD) is the most common inherited kidney disorder and a leading cause of kidney failure worldwide. Disease progression is driven by cyst expansion, tubular injury, and maladaptive metabolic and hemodynamic changes. Tolvaptan remains the only FDA-approved disease-modifying therapy, yet its tolerability and safety profile highlight the need for additional strategies. Sodium-glucose cotransporter-2 inhibitors (SGLT2i), initially developed for glycemic control, have demonstrated robust kidney- and cardio- protective effects across diverse patient populations, including those without diabetes. By lowering intraglomerular pressure, metabolic reprogramming, and attenuating hypoxic microenvironment and inflammation, SGLT2i target mechanisms that are relevant to ADPKD. However, concerns that SGLT2i may provoke osmotic diuresis and activate vasopressin led to systematic exclusion of patients with ADPKD from pivotal outcome trials. The 2025 KDIGO ADPKD guidelines explicitly advise against the use of SGLT2i for slowing kidney function decline in ADPKD. In this review, we examine mechanistic intersections between SGLT2i and ADPKD pathophysiology, summarize available preclinical and early clinical data, and discuss ongoing large trials designed to address safety and efficacy of SGLT2i in patients with ADPKD. We also highlight the importance of genetic heterogeneity, as most ongoing trials are enriched for rapid progressors carrying PKD1 or PKD2 pathogenic variants, while other genotypes such as DNAJB11 , ALG8 , and ALG9 , often associated with greater interstitial fibrosis, are underrepresented. Substratification of patients by genotype, risk of progression, and comorbidities will be essential to guide precision application of SGLT2i. Whether SGLT2i can ultimately be positioned as an adjunctive or standalone therapy for ADPKD remains unresolved.
IntroductionHypoglycemia is a common complication in diabetic nephropathy (DN) patients undergoing hemodialysis. Early detection is essential to prevent adverse outcomes. A calculator-based clinical tool (cyclic hypoglycemia calculator) was developed to estimate hypoglycemia risk and guide additional glucose needs. This study aimed to analyze the effect of using the calculator on preventing hypoglycemia during hemodialysis. MethodsA quasi-experimental pre–post test control group design was conducted among hemodialysis patients at Dr. Moewardi Hospital (March–July 2024). Samples were selected via simple random sampling: odd medical record numbers for the control group and even numbers for the intervention group. The intervention group received hypoglycemia-risk calculation and glucose adjustment recommendations, while the control group followed standard procedures. Blood glucose levels were measured before and after 4-hour hemodialysis using a standardized glucometer. Data were homogeneous (P=0.903) and non-normally distributed (P=0.00), so the Mann–Whitney test was applied. ResultsThere was no significant difference in blood glucose levels between groups (P=0.811). Pre-dialysis glucose levels were similar (115.45 vs. 114.71 mg/dL), and post-dialysis levels remained comparable (99.39 vs. 98.21 mg/dL). In the control group, 33% experienced increased glucose, 3% remained unchanged, and 64% decreased, with an average reduction of 33.67 mg/dL. In the intervention group, 36% increased and 64% decreased, with an average reduction of 24.5 mg/dL. ConclusionsThe hypoglycemia-deterrent calculator did not produce significant differences in glucose levels compared with standard care. However, its use showed 75% efficiency in reducing unnecessary D40% administration. Further studies are recommended to refine D40% dosing strategies during hemodialysis based on individualized risk scoring.